Pesquisa: SS-31 (Elamipretide)

Mitochondria-targeted peptide — restores cellular energy production

SS-31 (Elamipretide) Research Papers & Clinical Studies

SS-31 (Elamipretide) is a peptide studied for its potential therapeutic effects. Mitochondria-targeted peptide — restores cellular energy production This page indexes all published research papers, clinical trials, and scientific studies related to SS-31 (Elamipretide) that are available in the PepsReview research library. Each paper includes metadata such as journal name, publication year, citation count, study type, and a summary of key findings. Where available, we provide direct links to the original publication and DOI references.

Researchers can use this index to quickly locate evidence supporting specific SS-31 (Elamipretide) applications, compare study designs, and evaluate the strength of clinical evidence. Papers are sorted by relevance and citation count. There are currently 5 research papers indexed for SS-31 (Elamipretide).

For vendor pricing, user reviews, and a complete peptide profile including mechanism of action, benefits, side effects, and regulatory status, visit the main SS-31 (Elamipretide) profile page.

SS-31 (Elamipretide)

Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice

J Neuroinflammation 2019 140 Animal Study

An animal study where elamipretide improved mitochondrial dysfunction, synaptic signalling and memory measures in aged mice. Frequently cited in longevity-research circles as preclinical support for mitochondria-focused interventions — still pre-human.

Elamipretide (SS-31) treatment attenuates age-associated post-translational modifications of heart proteins

Geroscience 2021 100 Research Article

Elamipretide (SS-31) treatment reduces age-related post-translational protein changes in animal models. The study adds mechanistic detail on how a mitochondria-targeted peptide can interact with oxidative stress pathways, complementing the cardiac work on the same compound.

The mitochondrially targeted peptide elamipretide (SS-31) improves ADP sensitivity in aged mitochondria by increasing uptake through the adenine nucleotide translocator (ANT)

Geroscience 2023 60 Research Article

A 2023 paper reporting that elamipretide (SS-31) improves ADP-ribose recycling in mitochondria and supports energy metabolism under stress. Relevant for understanding targeted mitochondrial peptides and how cardiolipin binding is used as a design principle.

SS-31@Fer-1 Alleviates ferroptosis in hypoxia/reoxygenation cardiomyocytes via mitochondrial targeting

Biomed Pharmacother 2025 20 Research Article

Targeting mitochondrial ferroptosis presents a promising strategy for mitigating myocardial ischemia-reperfusion (I/R) injury.. This study aims to evaluate the efficacy of the mitochondrial-targeted ferroptosis inhibitor SS-31@Fer-1 (elamipretide@ferrostatin1) in reducing myocardial I/R injury.. SS-31@Fer-1 was synthesized and applied to H9C2 cells subjected to hypoxia/reoxygenation (H/R) to.

Targeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle Performance in a HFpEF Rat Model

Circ Heart Fail 2026 10 Animal Study

Study investigating SS-31 (Elamipretide): Targeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle Performance in a HFpEF Rat Model.